These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 22077934)
21. Percent free PSA as an additional measure in a prostate cancer screen. Miele ME Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982 [TBL] [Abstract][Full Text] [Related]
22. [The incidence of the variability of the free PSA/total PSA ratio on the early diagnosis of prostate cancer]. de La Taille A; Houlgatte A; Houdelette P; Berlizot P; Fournier R; Ricordel I Prog Urol; 1997 Jun; 7(3):455-63. PubMed ID: 9273075 [TBL] [Abstract][Full Text] [Related]
23. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. Vashi AR; Wojno KJ; Henricks W; England BA; Vessella RL; Lange PH; Wright GL; Schellhammer PF; Weigand RA; Olson RM; Dowell BL; Borden KK; Oesterling JE Urology; 1997 Jan; 49(1):19-27. PubMed ID: 9000179 [TBL] [Abstract][Full Text] [Related]
24. Value of prostate-specific antigen and prostate-specific antigen density in detection of prostate cancer in an Iranian population of men. Ghafoori M; Varedi P; Hosseini SJ; Asgari M; Shakiba M Urol J; 2009; 6(3):182-8. PubMed ID: 19711272 [TBL] [Abstract][Full Text] [Related]
25. Prospective evaluation of prostate cancer detection by prostate specific antigen related parameters: comparison in serum and plasma samples. Egawa S; Suyama K; Matsumoto K; Kuwao S; Baba S J Urol; 2002 Jan; 167(1):97-102. PubMed ID: 11743284 [TBL] [Abstract][Full Text] [Related]
26. [The detection rate of prostate cancer in different prostate-specific antigen (PSA) levels in Chinese men]. Li M; Na YQ Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(1):16-8. PubMed ID: 18346372 [TBL] [Abstract][Full Text] [Related]
27. Comparison of different prostate-specific antigen cutpoints for early detection of prostate cancer: results of a large screening study. Reissigl A; Pointner J; Horninger W; Ennemoser O; Strasser H; Klocker H; Bartsch G Urology; 1995 Nov; 46(5):662-5. PubMed ID: 7495117 [TBL] [Abstract][Full Text] [Related]
28. Detection of prostatic carcinoma: the role of TRUS, TRUS guided biopsy, digital rectal examination, PSA and PSA density. Men S; Cakar B; Conkbayir I; Hekimoglu B J Exp Clin Cancer Res; 2001 Dec; 20(4):473-80. PubMed ID: 11876539 [TBL] [Abstract][Full Text] [Related]
29. A multicenter study on the detection of prostate cancer by digital rectal examination and prostate-specific antigen in men with or without urinary symptoms. Cooperative Group for Diagnosis of Prostate Cancer. Eur Urol; 1997; 32(2):133-9. PubMed ID: 9286642 [TBL] [Abstract][Full Text] [Related]
30. Current and projected annual direct costs of screening asymptomatic men for prostate cancer using prostate-specific antigen. Krahn MD; Coombs A; Levy IG CMAJ; 1999 Jan; 160(1):49-57. PubMed ID: 9934343 [TBL] [Abstract][Full Text] [Related]
31. Screening for prostatic carcinoma with prostate specific antigen. Waidelich R; Jansen HM; Stieber P; Schmeller N; Lamerz R; Werdan K; Fateh-Moghadam A Anticancer Res; 1997; 17(4B):2979-81. PubMed ID: 9329580 [TBL] [Abstract][Full Text] [Related]
32. The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. Bangma CH; Rietbergen JB; Kranse R; Blijenberg BG; Petterson K; Schröder FH J Urol; 1997 Jun; 157(6):2191-6. PubMed ID: 9146612 [TBL] [Abstract][Full Text] [Related]
33. Comparison of digital rectal examination and prostate specific antigen in early detection of prostate cancer. Galić J; Karner I; Cenan L; Tucak A; Hegedus I; Pasini J; Bilandzija-Peranović M; Mihaljević S Coll Antropol; 2003; 27 Suppl 1():61-6. PubMed ID: 12955893 [TBL] [Abstract][Full Text] [Related]
34. [Focus on the screening for prostate cancer by PSA]. Roumeguère T; Van Velthoven R Rev Med Brux; 2013 Sep; 34(4):311-9. PubMed ID: 24195246 [TBL] [Abstract][Full Text] [Related]
35. Volume-adjusted prostate-specific antigen (PSA) variables in detecting impalpable prostate cancer in men with PSA levels of 2-4 ng/mL: transabdominal measurement makes a significant contribution. Kobayashi T; Kawahara T; Nishizawa K; Ogura K; Mitsumori K; Ide Y BJU Int; 2005 Jun; 95(9):1245-8. PubMed ID: 15892809 [TBL] [Abstract][Full Text] [Related]
36. Cost analysis of prostate cancer detection including the prostate health index (phi). Mathieu R; Castelli C; Fardoun T; Peyronnet B; Shariat SF; Bensalah K; Vincendeau S World J Urol; 2019 Mar; 37(3):481-487. PubMed ID: 29980838 [TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of magnetic resonance (MR) imaging and MR-guided targeted biopsy versus systematic transrectal ultrasound-guided biopsy in diagnosing prostate cancer: a modelling study from a health care perspective. de Rooij M; Crienen S; Witjes JA; Barentsz JO; Rovers MM; Grutters JP Eur Urol; 2014 Sep; 66(3):430-6. PubMed ID: 24377803 [TBL] [Abstract][Full Text] [Related]
38. Cost-Effectiveness Analysis of Prostate-Specific Antigen Screening Among Chinese Men. Zhao G; Shao Y; Zhang N; Wang J; Yuan L; Sun X; Shi L Value Health Reg Issues; 2020 May; 21():272-279. PubMed ID: 32402819 [TBL] [Abstract][Full Text] [Related]
39. Cost implications of PSA screening differ by age. Rao K; Liang S; Cardamone M; Joshu CE; Marmen K; Bhavsar N; Nelson WG; Ballentine Carter H; Albert MC; Platz EA; Pollack CE BMC Urol; 2018 May; 18(1):38. PubMed ID: 29743049 [TBL] [Abstract][Full Text] [Related]
40. The cost-effectiveness of prostate cancer screening using the Stockholm3 test. Karlsson AA; Hao S; Jauhiainen A; Elfström KM; Egevad L; Nordström T; Heintz E; Clements MS PLoS One; 2021; 16(2):e0246674. PubMed ID: 33630863 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]